The estimated Net Worth of Kurt Graves is at least $606 mil dollars as of 16 April 2019. Mr. Graves owns over 4,800 units of Seres Therapeutics Inc stock worth over $5,775 and over the last 17 years he sold MCRB stock worth over $522,374. In addition, he makes $78,152 as Independent Director at Seres Therapeutics Inc.
Sign up
Mr. Graves MCRB stock SEC Form 4 insiders trading
Kurt has made over 15 trades of the Seres Therapeutics Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he sold 4,800 units of MCRB stock worth $107,136 on 16 April 2019.
The largest trade he's ever made was exercising 25,000 units of Seres Therapeutics Inc stock on 6 July 2015 worth over $183,500. On average, Kurt trades about 1,681 units every 72 days since 2007. As of 16 April 2019 he still owns at least 5,500 units of Seres Therapeutics Inc stock.
You can see the complete history of Mr. Graves stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kurt Graves biography
Kurt C. Graves serves as Independent Director of the Company. Mr. Graves has been the Chairman, President and Chief Executive Officer of Intarcia Therapeutics, Inc. (“Intarcia”), a biotechnology company, since April 2012 and Executive Chairman from August 2010 to April 2012. Mr. Graves previously served as Executive Chairman of Biolex Therapeutics, a biopharmaceutical company, from November 2010 to March 2012, and as Executive Chairman of Intarcia from August 2010 to April 2012. Previously, he served as Executive Vice President, Chief Commercial Officer and Head of Strategic Development at Vertex Pharmaceuticals Inc. (“Vertex”), from July 2007 to October 2009. Prior to joining Vertex, Mr. Graves held various leadership positions at Novartis Pharmaceuticals Corporation (“Novartis Corp.”), from 1999 to June 2007, including the Chief Marketing Officer for the pharmaceuticals division of Novartis Corp. from September 2003 to June 2007. He also has served on the boards directors of Intarcia Therapeutics, Inc. since 2010, Radius Health, Inc. since 2011, and Achillion Pharmaceuticals, Inc. since 2012. Mr. Graves received a B.S. in Biology from Hillsdale College.
What is the salary of Kurt Graves?
As the Independent Director of Seres Therapeutics Inc, the total compensation of Kurt Graves at Seres Therapeutics Inc is $78,152. There are 7 executives at Seres Therapeutics Inc getting paid more, with Eric Shaff having the highest compensation of $2,032,550.
How old is Kurt Graves?
Kurt Graves is 52, he's been the Independent Director of Seres Therapeutics Inc since 2015. There are 12 older and 8 younger executives at Seres Therapeutics Inc. The oldest executive at Seres Therapeutics Inc is Dennis Ausiello, 74, who is the Independent Director.
What's Kurt Graves's mailing address?
Kurt's mailing address filed with the SEC is C/O SERES THERAPEUTICS, INC., 101 CAMBRIDGE PARK DRIVE, CAMBRIDGE, MA, 02140.
Insiders trading at Seres Therapeutics Inc
Over the last 9 years, insiders at Seres Therapeutics Inc have traded over $37,132,594 worth of Seres Therapeutics Inc stock and bought 17,627,131 units worth $47,525,463 . The most active insiders traders include Noubar Afeyan, Health Ltp Fund General Par... y Health Science Us Holdings,.... On average, Seres Therapeutics Inc executives and independent directors trade stock every 35 days with the average trade being worth of $251,393. The most recent stock trade was executed by Thomas Des Rosier on 15 August 2024, trading 2,656 units of MCRB stock currently worth $2,789.
What does Seres Therapeutics Inc do?
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.
What does Seres Therapeutics Inc's logo look like?
Complete history of Mr. Graves stock trades at Pulmatrix Inc, Radius Recycling, Seres Therapeutics Inc y Vertex Pharmaceuticals
Seres Therapeutics Inc executives and stock owners
Seres Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Eric Shaff,
President, Chief Executive Officer, Director -
Eric D. Shaff M.B.A.,
Pres, CEO & Director -
Thomas DesRosier,
Chief Legal Officer, Executive Vice President and Secretary -
Matthew Henn,
Executive Vice President, Chief Scientific Officer -
Thomas J. DesRosier,
Chief Legal Officer, Exec. VP & Sec. -
Dr. David S. Ege Ph.D.,
Exec. VP & Chief Technology Officer -
Richard Kender,
Independent Director -
Kurt Graves,
Independent Director -
Meryl Zausner,
Independent Director -
Willard Dere,
Independent Director -
Gregory Behar,
Independent Director -
Dennis Ausiello,
Independent Director -
Stephen Berenson,
Independent Chairman of the Board -
David Ege,
Executive Vice President, Chief Technology Officer -
Jayne Gansler,
Chief People Officer, Executive Vice President -
Terri Young,
Executive Vice President, Chief Commercial and Strategy Officer -
Lisa von Moltke,
Executive Vice President, Chief Medical Officer -
Paul Biondi,
Independent Director -
Carlo Tanzi,
Head of Investor Relations and Corporate Communications -
John Aunins,
Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer -
Marcus Chapman,
Senior Vice President - Finance and Principal Financial and Accounting Officer -
Dr. John G. Aunins Ph.D.,
Sr. Advisor -
Dr. Matthew R. Henn Ph.D.,
Exec. VP & Chief Scientific Officer -
David A. Arkowitz M.B.A.,
Exec. VP, CFO & Head of Bus. Devel. -
James R. Weston,
Sr. VP of Regulatory Affairs -
Jayne M. Gansler,
Exec. VP & Chief People Officer -
Jeff York,
VP of HR -
Noubar Flagship Ventures Fu...,
-
Peter Barton Hutt,
Director -
Michele Trucksis,
See Remarks -
David N Cook,
See Remarks -
Noubar Afeyan,
Director -
Health Science Us Holdings,...,
-
Lorence H. Kim,
Director -
Wael Hashad,
EVP & Chief Commercial Officer -
Teresa L. Young,
See Remarks -
Paula Cloghessy,
See Remarks -
Marella Thorell,
See Remarks -
Roger Pomerantz,
President and CEO -
Kevin Horgan,
Chief Medical Officer and EVP -
Werner Cautreels,
Director -
Noubar Flagship Ventures Fu...,
-
Ventures Fund Iv General Pa...,
-
Health Ltp Fund General Par...,
-
David Arkowitz,
Chief Financial Officer -
Health Ltp Fund General Par...,
-
Claire Fraser,